CONCENTRATIONS AND CREDIT RISK |
12 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Risks and Uncertainties [Abstract] | |
| CONCENTRATIONS AND CREDIT RISK | NOTE 13. CONCENTRATIONS AND CREDIT RISK
Revenues
Two customers accounted for approximately 74% of the Company’s revenues for the year ended March 31, 2026. These two customers accounted for approximately 64% and 10% of revenues each, respectively.
Two customers accounted for approximately 58% of the Company’s revenues for the year ended March 31, 2025. These two customers accounted for approximately 39% and 19% of revenue each, respectively.
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Accounts Receivable
One customer accounted for approximately 69% of the Company’s accounts receivable as of March 31, 2026.
Three customers accounted for approximately 75% of the Company’s accounts receivable as of March 31, 2025. These three customers accounted for approximately 46%, 19%, and 10% of accounts receivable each, respectively.
Purchasing
Three suppliers accounted for approximately 73% of the Company’s purchases of raw materials for the year ended March 31, 2026. These three customers accounted for approximately 36%, 24%, and 13% of purchasing each, respectively.
Three suppliers accounted for approximately 69% of the Company’s purchases of raw materials for the year ended March 31, 2025. These three customers accounted for approximately 43%, 13%, and 13%, of purchasing each, respectively.
|